Neonatologie – Ausschließliche Ernährung mit humaner Milch: Rechnet sich das?

2021 ◽  
Vol 26 (01) ◽  
pp. 15-15
Keyword(s):  
High Risk ◽  
Economic Analysis ◽  
Human Milk ◽  
Canadian Hospital ◽  
Hospital Perspective

van Katwyk S et al. Economic Analysis of Exclusive Human Milk Diets for High-Risk Neonates, a Canadian Hospital Perspective. Breastfeed Med 2020; 15 (6): 377–386. DOI: 10.1089/bfm.2019.0273 Frühgeborene profitieren hinsichtlich einer Vielzahl potenzieller Komplikationen, beispielsweise der nekrotisierenden Enterokolitis, der Retinopathie, der Sepsis sowie der bronchopulmonalen Dysplasie, von einer ausschließlichen Ernährung mit humaner Milch, bei welcher die Milch der eigenen Mutter bzw. Donormilch mit aus pasteurisierter Spendermilch gewonnenem Fortifier angereichert wird. Ist dieses Vorgehen auch unter Kostenaspekten vertretbar?

Economic Analysis of Exclusive Human Milk Diets for High-Risk Neonates, a Canadian Hospital Perspective

2020 ◽  
Vol 15 (6) ◽  
pp. 377-386 ◽  
Author(s):  
Sasha van Katwyk ◽  
Emanuela Ferretti ◽  
Srishti Kumar ◽  
Brian Hutton ◽  
JoAnn Harrold ◽  
...  
Keyword(s):  
High Risk ◽  
Economic Analysis ◽  
Human Milk ◽  
Canadian Hospital ◽  
Hospital Perspective

Cost-Effectiveness Analysis of Abciximab: A Canadian Hospital Perspective

1998 ◽  
Vol 32 (5) ◽  
pp. 536-542 ◽  
Author(s):  
Peter J Zed ◽  
Luciana Frighetto ◽  
Rubina Sunderji ◽  
Carlo A Marra
Keyword(s):  
Cost Effectiveness ◽  
High Risk ◽  
Treatment Strategies ◽  
Economic Evaluations ◽  
Decision Analytic Model ◽  
Canadian Hospital ◽  
Hospital Perspective ◽  
High Risk Patients ◽  
Risk Patients ◽  
The Cost

OBJECTIVE: To assess the cost-effectiveness of abciximab therapy versus traditional practice in high-risk patients receiving percutaneous transluminal coronary angioplasty (PTCA) from a Canadian hospital perspective. DESIGN: A predictive decision analytic model using published clinical and economic evaluations, as well as costs of medical care in Canada. SUBJECTS: High-risk PTCA patients as defined by the Evaluation of c7E3 for Prevention of Ischemic Complications trial and the c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina trial. INTERVENTIONS: Two treatment strategies were compared: (1) abciximab 0.25 mg/kg intravenous bolus 10 minutes prior to PTCA followed by abciximab 10 4μg/min intravenous infusion for 12 hours after the procedure, and (2) no abciximab adjunctive therapy at the time of PTCA. Both treatment strategies were combined with intravenous heparin up to 100 units/kg bolus pre-PTCA followed by bolus doses for 1 hour after PTCA per the protocol. Cumulative outcomes were considered up to 6 months after initial PTCA. RESULTS: At 6 months, 29% of the patients in the abciximab treatment arm compared with 33% in the no abciximab arm achieved one of the primary events. The most common adverse event experienced was major bleeding at 4% in the abciximab treatment arm versus 1.6% in the no abciximab arm. The average cost per patient for each strategy was $3261 Can ($1 Can = $0.686 US) (abciximab arm) versus $2073 Can (no abciximab arm), resulting in an incremental cost-effectiveness ratio of $29 700 Can per event-free patient. In univariate sensitivity analyses, the only controllable factor that changed the results of the cost-effectiveness outcome was the cost of abciximab. CONCLUSIONS: Although the use of abciximab as an adjunct to PTCA results in a reduction in event rates in high-risk patients compared with traditional treatment, there is an increased cost associated with this strategy.

Thoughts on the Monetary Value of Human Milk

2013 ◽  
Vol 4 (4) ◽  
pp. 155-158
Author(s):  
Nikki Lee
Keyword(s):  
Economic Analysis ◽  
Human Milk ◽  
Peer Counseling ◽  
Valuable Resource ◽  
Breastfeeding Support ◽  
Budget Planning ◽  
Step Process ◽  
Monetary Value

U.S. legislators have recently considered cutting funding for breastfeeding peer counseling. One reason why they might decide to make these cuts is that breastfeeding and human milk are invisible to them. It is easy to get rid of something that isn’t seen or valued. If there were a way to make this valuable resource—human milk—visible, and this information was given to our legislators, perhaps the door could be opened to including breastfeeding support in budget planning. Here is a step-by-step process to generate the value of human milk in your state or community, so that women’s contributions can be part of economic analysis.

Cost-Minimization Analysis of Piperacillin/Tazobactam versus Imipenem/Cilastatin for the Treatment of Serious Infections: A Canadian Hospital Perspective

1999 ◽  
Vol 33 (2) ◽  
pp. 156-162 ◽  
Author(s):  
Fawziah O Marra ◽  
Luciana O Frighetto ◽  
Carlo A Marra ◽  
Kenna M Sleigh ◽  
H Grant Stiver ◽  
...  
Keyword(s):  
Cost Minimization ◽  
Canadian Hospital ◽  
Hospital Perspective ◽  
Cost Minimization Analysis ◽  
Serious Infections
Sign in / Sign up

Export Citation Format

Share Document